Skip to content
value.today

Catabasis Pharmaceuticals Inc.

Total raised
$172 M
5 rounds on record
Latest round
$110 M
Feb 2021
First round on record
Apr 2010
Today
Private
See the company page

Catabasis Pharmaceuticals Inc. is listed today as Catabasis Pharmaceuticals: market value, financials and filings are on its company page.

Funding rounds

5 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Catabasis Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Feb 2021$110 MNo. 5$50 to $250 million

Catabasis Pharmaceuticals Inc.: Raise no. 5, Feb 2021

Investors in this round

23 investors had bought by the notice of Feb 8, 2021: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Catabasis Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$110 M of $110 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$5,500,528
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew C. Komjathy · Executive Officer
  • Andrew C. Nichols · Executive Officer
  • Ben T. Harshbarger · Executive Officer
  • Jill C. Milne · Executive Officer, Director
  • Joanne C. Donovan · Executive Officer
  • Noah T. Clauser · Executive Officer
  • Fred T. Callori · Director
  • Gregg T. Lapointe · Director
  • Hugh T. Cole · Director
  • Joanne T. Beck · Director
  • Jonathan T. Violin · Director
  • Kenneth D. Bate · Director
  • Michael D. Kishbauch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Jefferies LLC (CRD 2347) · New York, New YorkSold in all US states

Signed by Ben Harshbarger, Senior Vice President, General Counsel. Source: SEC Form D, newest notice filed Feb 8, 2021. Read the notice at the SEC.

equitySEC
Jan 2021$176 MIssued in a merger or acquisition$50 to $250 million

Catabasis Pharmaceuticals Inc.: Private sale, Jan 2021

Investors in this round

6 investors had bought by the notice of Feb 8, 2021: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Catabasis Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$176 M of $176 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew C. Komjathy · Executive Officer
  • Andrew C. Nichols · Executive Officer
  • Ben T. Harshbarger · Executive Officer
  • Jill C. Milne · Executive Officer, Director
  • Joanne C. Donovan · Executive Officer
  • Noah T. Clauser · Executive Officer
  • Fred T. Callori · Director
  • Gregg T. Lapointe · Director
  • Hugh T. Cole · Director
  • Joanne T. Beck · Director
  • Jonathan T. Violin · Director
  • Kenneth D. Bate · Director
  • Michael D. Kishbauch · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “Acquisition of Quellis Biosciences, Inc.”

Signed by Ben Harshbarger, Senior Vice President, General Counsel. Source: SEC Form D, newest notice filed Feb 8, 2021. Read the notice at the SEC.

equity, optionsSEC
Mar 2015$12 MNo. 4$10 to $50 million

Catabasis Pharmaceuticals Inc.: Raise no. 4, Mar 2015

Investors in this round

20 investors had bought by the notice of Mar 31, 2015: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Catabasis Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $20 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ian C. Sanderson · Executive Officer
  • Jill C. Milne · Executive Officer, Director
  • Jean C. George · Director
  • Kenneth C. Bate · Director
  • Michael C. Ross · Director
  • Nicholas C. Galakatos · Director
  • Ron C. Laufer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jill Milne, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 31, 2015. Read the notice at the SEC.

equitySEC
Oct 2013$32 MNo. 3$10 to $50 million

Catabasis Pharmaceuticals Inc.: Raise no. 3, Oct 2013

Investors in this round

11 investors had bought by the notice of Nov 15, 2013: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Catabasis Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$32 M of $32 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jill Milne · Executive Officer, Director
  • Michael Jirousek · Executive Officer
  • Michael Ross · Director
  • Nicholas Galakatos · Director
  • Ron Laufer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jill Milne, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 15, 2013. Read the notice at the SEC.

equitySEC
Jan 2013$9 MNo. 2$2 to $10 million

Catabasis Pharmaceuticals Inc.: Raise no. 2, Jan 2013

Investors in this round

14 investors had bought by the notice of Jun 27, 2013: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Catabasis Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$9 M of $9 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jill Milne · Executive Officer, Director
  • Michael Jirousek · Executive Officer
  • Michael Ross · Director
  • Nicholas Galakatos · Director
  • Ron Laufer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jill Milne, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 27, 2013. Read the notice at the SEC.

equitySEC
Apr 2010$8 MNo. 1$2 to $10 million

Catabasis Pharmaceuticals Inc.: Raise no. 1, Apr 2010

Investors in this round

15 investors had bought by the notice of Apr 14, 2010: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 18 investors are named for Catabasis Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$8 M of $40 M offered; $32 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jill Milne · Executive Officer, Director
  • Michael Jirousek · Executive Officer
  • Jeffrey Leiden · Director
  • Maggie LeFlore · Director
  • Michael Ross · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Jill Milne, President. Source: SEC Form D, newest notice filed Apr 14, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Catabasis Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2021).

    SEC Form D · Feb 2021

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2021

That is all the official record says: Catabasis Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Catabasis Pharmaceuticals Inc. are on record.

Investors#

18 named in official filings. Open an investor to see everything it has backed.

Investors in Catabasis Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Advanced Technology Ventures VIII LPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
ATV Associates VIII, L.L.C.Othernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Clarus Lifesciences II, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Clarus Ventures II GP, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Clarus Ventures II, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Jill C. MilnePersonnot statednot statedHeld Series A and B preferred stock, director (Form 3, 2015)SEC Form 3
Joanne M. DonovanPersonnot statednot statedHeld Series B preferred stock (Form 3, 2015)SEC Form 3
MedImmune Ventures, Inc.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Michael JirousekPersonnot statednot statedHeld Series A and B preferred stock (Form 3, 2015)SEC Form 3
Perceptive Advisors LLCFund or asset managernot statednot statedHeld Series X preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Perceptive Life Sciences Master Fund LTDFund or asset managernot statednot statedHeld Series X preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Perceptive Xontogeny Venture Fund, LPVenture capitalnot statednot statedHeld Series X preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3
Rick ModiPersonnot statednot statedHeld Series B preferred stock (Form 3, 2015)SEC Form 3
SV Life Sciences Fund V (GP), LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
SV Life Sciences Fund V LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
SV Life Sciences Fund V Strategic Partners, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Svlsf V, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Xontogeny, LLCOthernot statednot statedHeld Series X preferred stock, 10% owner, director (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 23 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Catabasis Pharmaceuticals Inc.
NameRoleNamed in
Andrew C. KomjathyExecutive officerFeb 2021
Andrew C. NicholsExecutive officerFeb 2021
Ben T. HarshbargerExecutive officerFeb 2021
Jill C. MilneExecutive officerFeb 2021
Joanne C. DonovanExecutive officerFeb 2021
Noah T. ClauserExecutive officerFeb 2021
Ian C. SandersonExecutive officerMar 2015
Jill MilneExecutive officerNov 2013
Michael JirousekExecutive officerNov 2013
Fred T. CalloriDirectorFeb 2021
Gregg T. LapointeDirectorFeb 2021
Hugh T. ColeDirectorFeb 2021
Jill C. MilneDirectorFeb 2021
Joanne T. BeckDirectorFeb 2021
Jonathan T. ViolinDirectorFeb 2021
Kenneth D. BateDirectorFeb 2021
Michael D. KishbauchDirectorFeb 2021
Jean C. GeorgeDirectorMar 2015
Kenneth C. BateDirectorMar 2015
Michael C. RossDirectorMar 2015
Nicholas C. GalakatosDirectorMar 2015
Ron C. LauferDirectorMar 2015
Jill MilneDirectorNov 2013
Michael RossDirectorNov 2013
Nicholas GalakatosDirectorNov 2013
Ron LauferDirectorNov 2013
Jeffrey LeidenDirectorApr 2010
Maggie LeFloreDirectorApr 2010

About

Company in Cambridge, United States.